Exagamglogene autotemcel (exa-cel), a CRISPR-Cas9 gene-edited cell therapy, led to sustained improvements in health-related quality of life (HRQOL) for both adults and adolescents with ...
Patients with sickle cell disease and beta-thalassemia treated with exagamglogene autotemcel reported substantial and ...
The new Prescription Drug User Fee Act target date is now December 7, 2025. The Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for ...
(WASHINGTON — August 27, 2025) – Treatment with exagamglogene autotemcel (exa-cel) led to robust and sustained improvements in quality of life for patients with severe sickle cell disease (SCD) or ...
Hosted on MSN
Agios drops as FDA delays review of thalassemia drug
Agios Pharmaceuticals (NASDAQ:AGIO) fell ~17% in the premarket on Thursday after the U.S. FDA issued a three-month extension to the review period for the company’s lead asset, Pyrukynd, targeted at ...
Thanks to groundbreaking in-utero blood transfusion technology, what was once a fatal diagnosis in the womb can now result in live births. However, this medical advancement created a new challenge: a ...
In the beta thalassemia study, Dr. de la Fuente and his colleagues used two quality of life scales to evaluate outcomes in adult patients and two quality of life scales for adolescent patients. Unlike ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback